HoneyLab was founded by Dr. Shaun Holt and Laurence Greig in late 2009. Previously, Shaun trained as a pharmacist in the UK and then as a doctor in the UK. Shaun had spent most of his medical career to that point undertaking clinical studies for pharmaceutical companies. HoneyLab was formed in order to apply the same drug development processes to natural products.
Early HoneyLab products such as Honevo and Kanu, were developed from bees and their environment. HoneyLab has undertaken the world’s largest research programme of clinical research into the benefits of pharmaceutical-grade honey for skin diseases. Since then, the research programme has expanded to other sustainable resources, such as kanuka oil, which are likely to be effective health products.
We have a number of products already available and many more in development. Products are currently available through the Shop page on our website and some pharmacy stores in New Zealand. We are also in discussions with partners to make our products available globally.
Not many people know that the global giant GlaxoSmithKline started life as a milk products company near Palmerston North in the lower North Island of New Zealand – HoneyLab are aiming to emulate their success as a global supplier of high quality healthcare products.
2009 Company formed December 2009
2010 Honevo development work and IP protection started
2011 Development work on Kanu and Rubeeven
2012 Positive Kanu phase 2 studies
2013 Kanu released; Rubeeven released; positive Honevo phase 2 studies for acne, cold sores and rosacea
2014 Positive phase 3 acne and rosacea studies; Honevo launched
2015 Shaun was runner-up for New Zealander of the Year 2015 Awards, Innovator of the Year category; Melzest released (originally called Melsip); Rosacea phase 3 study published in BMJ Open
2016 Shaun gives TEDx talk on medical honey; Melzing released; partnership with Hikurangi Enterprises to develop kanuka oil products; HoneyLab become a NZTE Focus 700 company
2017 Quayside Holdings become cornerstone investor; Anthony Lawler appointed CEO; Melrest released
2018 Positive phase 3 cold sore study; kanuka oil phase 2 studies started
2019 Cold sores phase 3 study published in BMJ Open; Honevo patent granted in EU & USA; Honevo approved as a medical device in New Zealand; Shaun was a finalist in the EY Entrepreneur of the Year award
Why HoneyLab Exists
HoneyLab undertake extensive Research & Development to develop novel and effective natural products in a sustainable manner.
Our core principles are:
- Health products should have solid research behind them to show that they are effective and safe
- The products should be made in a sustainable manner
- The company contributes to the community
The HoneyLab Team
Anthony Lawler – CEO
Anthony brings a wealth of experience in the natural health, biotech, food and beverage industries. He has a strong track record of driving strong revenue growth and capital raising with leading companies such as A2 Milk, Vital Foods and more recently Good Heath Products.
Anthony has key skills in General Management, Sales, Marketing, Regulatory, Production, Supply Chain and New Product Development. He also brings a large amount of international market experience particularly in China, South Korea, Australia, USA, Hong Kong, Vietnam, Indonesia.
Dr Shaun Holt – CSO & Director
Dr Shaun Holt holds Pharmacy and Medicine degrees. He has been the Principal Investigator in over 50 clinical trials and has over 230 publications in the medical literature.
Shaun has been a regular contributor on TV1’s Breakfast programme and often appears on national radio shows. He is the author of 10 books including the bestseller “Natural Remedies That Really Work”, was a finalist in the 2015 New Zealander of the Year Awards in the Innovator category, and was a finalist in the 2019 New Zealand Entrepreneur of the Year Awards.
Julia Ammundsen – Commercial Manager
Julia brings 20 years of finance and retail experience to HoneyLab. As a foreign exchange trader in The National Banks treasury department, she managed the bank’s currency positions during the challenging London and New York time zones.
Julia also owned and ran a successful retail store for 10 years, managing all facets of the business. She holds a BSc from Victoria University and is passionate about proven natural medicines.
Dr Ian Boddy – Chair
Dr Ian Boddy, who has a PhD in organic chemistry, was a Research Fellow at Cambridge University and a Senior Research Leader with the large German agrochemicals company, Schering AG.
He is also well-known for his time with the New Zealand Crown Research Institute AgResearch as GM Commercial.
Brendon Barnes – Director
Brendon is the Chief Investment Officer for Quayside Holdings. Brendon comes from an investment banking background and spent 11 years working overseas with the Macquarie Group and the Abu Dhabi Investment Authority.
He holds a BCA (Accounting and Commercial Law) and a Graduate Diploma (Professional Accounting) from Victoria University. Brendon is a member of the Institute of Directors.